The cognitive safety of antimuscarinics in the treatment of overactive bladder.

George Araklitis, Dudley Robinson

Expert opinion on drug safety 2020 Oct

filter terms:

Overactive bladder is a common problem women suffer from, with its incidence increasing with age. The mainstay of treatment is antimuscarinic medication. There is growing evidence that antimuscarinics may increase the risk of cognitive impairment, dementia, and even death. This review explores the evidence that antimuscarinics increase the risk of cognitive impairment, dementia, and death. It evaluates how best to treat overactive bladder the older woman. The evidence suggests that antimuscarinics increase the risk of cognitive impairment and dementia in the older adult. Care should be taken to use an antimuscarinic that is less likely to cross the blood-brain barrier and thus reduce the risk of these significant adverse events. A patient's anticholinergic load also needs to be considered when treating this group. Other treatment options such as fluid management, bladder retraining, vaginal estrogens, mirabegron, Onabotulinum toxin A and neuromodulation can be used instead.

Citation

George Araklitis, Dudley Robinson. The cognitive safety of antimuscarinics in the treatment of overactive bladder. Expert opinion on drug safety. 2020 Oct;19(10):1303-1313